Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADU-S100
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
ADU-S100 is a synthetic cyclic dinucleotide (CDN) agonist of the Stimulator of Interferon Genes (STING) receptor. It activates all known human and mouse STING alleles, leading to the induction of cytokines and chemokines that drive a robust and durable antigen-specific T-cell mediated immune response against cancer cells. The drug is a bisphosphothioate analog of cyclic di-AMP with enhanced stability due to sulfur substitutions at the phosphate bridge, making it less susceptible to enzymatic hydrolysis. Preclinical studies have shown that intratumoral injection can cause regression of established tumors and generate systemic immune memory. ADU-S100 has advanced into phase I/II clinical trials for various solid tumors and lymphomas as an investigational immunotherapy agent[1][2][5][6].
- Other names
- 2'3'-c-di-AM(PS)2 (Rp,Rp)(R,R)-(2',3')c-diAM(PS)2(2',3')-Rp,Rp-c-diAMPSS
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on ADU-S100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADU-S100.